Ohio鈥檚 Drug-Pricing Ballot Question Triggers Voter Confusion
Millions of dollars in campaign spending and a media blitz of advertisements muddy public understanding of Issue 2, the Drug Price Relief Act.
Drug Costs
581-600 of 707 results
-
-
Health Companies Race To Catch UnitedHealth As Amazon Laces Up
UnitedHealth, a health industry goliath, has its hand in doctors鈥 offices, surgery centers, technology services and prescription drugs. It is the industry model, and CVS and Aetna, says one expert, are 鈥榳annabes.鈥
By Chad Terhune -
House Republicans Aim To Yank Tax Credits For Orphan Drugs
House Republicans want to repeal federal tax credits that have helped spur a boom in orphan drugs for rare diseases.
-
Timeline: Insulin Market Under Scrutiny
A flurry of federal and state probes have targeted insulin manufacturers and pharmacy benefit managers 鈥 middlemen in the prescription drug-pricing pipeline. Here, we connect the legal dots.
-
Flurry Of Federal And State Probes Target Insulin Drugmakers And Pharma Middlemen
Over the past two years, a powerful federal prosecutor and several state attorneys general have launched investigations related to diabetes drugs.
-
New Law Challenges ‘Evils’ Of Pharma Profits, California Governor Claims
Gov. Jerry Brown signed the measure, which takes effect next year and will require drug companies to publicly justify big price increases.
-
Eyes Fixed On California As Governor Ponders Inking Drug Price Transparency Bill
"If it gets signed by this governor, it's going to send shock waves throughout the country,鈥 one legislator says. Pharma has spent $16.8 million lobbying against this bill and other drug laws in California.
-
Hepatitis C Drug鈥檚 Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment
The drug, sold under the name Mavyret, can cure all six genetic types of the liver disease in eight weeks at a cost of $26,400, well below other options.
-
Do Pharma’s Claims On Drug Prices Pass The Smell Test? We Found 5 Stinkers.
Drug companies are in the midst of a glossy publicity campaign to stop attempts to control rising pharma costs. But the devil is in the details.
By Jay Hancock -
Absent Federal Action, States Take The Lead On Curbing Drug Costs
Congress has yet to take substantive action on this growing consumer concern, but a number of states are flexing their cost-control muscle.
-
Out-Of-Pocket Costs Often Keep Pricey New Cholesterol Drugs Out Of Reach, Study Finds
Research published this week by JAMA Cardiology analyzed pharmacy claims data related to a new class of cholesterol-lowering drugs.
-
Right After Trump Blamed High Drug Prices On Campaign Cash, Drugmakers Gave More
At a political rally in March, President Donald Trump said drug prices are 鈥渙utrageous鈥 and blamed campaign contributions. Drugmakers funneled nearly $280,000 to Congress the very next day.
By Sydney Lupkin and Elizabeth Lucas -
News Analysis
Everyone Says We Must Control Exorbitant Drug Prices. So, Why Don鈥檛 We?
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
By Jay Hancock -
High On Drugs? Anthem Cites Soaring Drug Costs To Justify 35% Rate Hike in California
The company鈥檚 drug spending prediction, far above other insurers in the individual market, has experts scratching their heads. Anthem cites market volatility.
听By Chad Terhune -
The Orphan Drug Machine
FDA Moves To Guard Against Abuse Of 鈥極rphan Drug鈥 Program
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of 鈥渙rphan drugs鈥 while closing a loophole that allowed drugmakers to skip pediatric testing.
-
Facebook Live: The Prescription Drug Pricing Pipeline
In this Facebook Live, KHN鈥檚 Julie Appleby talks with Stephanie Stapleton and answers readers鈥 questions about the prescription drug pricing pipeline and the industry stakeholders who have a role in what you pay.
-
鈥楤reakthrough鈥 Leukemia Drug Also Portends 鈥楺uantum Leap鈥 In Cost
A genetically altered cancer drug, based on CAR T-cell therapies, could be a big success with leukemia patients but at a staggering cost.
By Liz Szabo -
Podcast: ‘What The Health?’ Why Is It So Difficult To Control Drug Prices?
In this episode of 鈥淲hat the Health?鈥 Mary Agnes Carey of Kaiser Health News, Sarah Karlin-Smith of Politico, Margot Sanger-Katz of The New York Times and Julie Appleby of Kaiser Health News discuss the recent extension of cost-sharing subsidies for millions of low-income beneficiaries on the Affordable Care Act鈥檚 marketplaces and the state of play on Capitol Hill and in the states concerning initiatives to lower prescription drug costs.
-
Climbing Cost Of Decades-Old Drugs Threatens To Break Medicaid Bank
Medicaid spent billions more in 2016 than the year before on decades-old prescription drugs, including many generics, a Kaiser Health News data analysis shows.
-
Hospitals Slashed Use Of Two Heart Drugs After Huge Price Hikes
Hospital use of two popular heart medicines, nitroprusside and isoproterenol, dramatically dropped after the prices for both soared.